| A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma O Hamid, H Schmidt, A Nissan, L Ridolfi, S Aamdal, J Hansson, M Guida, ... Journal of translational medicine 9, 1-16, 2011 | 623 | 2011 |
| Evaluation of in vivo labelled dendritic cell migration in cancer patients R Ridolfi, A Riccobon, R Galassi, G Giorgetti, M Petrini, L Fiammenghi, ... Journal of Translational Medicine 2, 1-11, 2004 | 155 | 2004 |
| Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy R Danielli, R Ridolfi, V Chiarion-Sileni, P Queirolo, A Testori, R Plummer, ... Cancer Immunology, Immunotherapy 61, 41-48, 2012 | 144 | 2012 |
| Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases P Queirolo, F Spagnolo, PA Ascierto, E Simeone, P Marchetti, A Scoppola, ... Journal of neuro-oncology 118, 109-116, 2014 | 129 | 2014 |
| Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients L Ridolfi, M Petrini, AM Granato, G Gentilcore, E Simeone, PA Ascierto, ... Journal of translational medicine 11, 1-10, 2013 | 77 | 2013 |
| Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial G Procopio, E Verzoni, S Bracarda, S Ricci, C Sacco, L Ridolfi, C Porta, ... British journal of cancer 104 (8), 1256-1261, 2011 | 75 | 2011 |
| Ipilimumab in advanced melanoma: reports of long-lasting responses A Farolfi, L Ridolfi, M Guidoboni, SVL Nicoletti, S Piciucchi, L Valmorri, ... Melanoma research 22 (3), 263-270, 2012 | 72 | 2012 |
| Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide-and dacarbazine-based regimens V Chiarion-Sileni, M Guida, L Ridolfi, A Romanini, P Del Bianco, ... British journal of cancer 104 (12), 1816-1821, 2011 | 65 | 2011 |
| Unexpected high response rate to traditional therapy after dendritic cell‐based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis L Ridolfi, M Petrini, L Fiammenghi, AM Granato, V Ancarani, E Pancisi, ... Journal of Immunology Research 2010 (1), 504979, 2010 | 65 | 2010 |
| Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin‐2 after radical hepatic resection for colorectal liver metastases: 5‐year analysis A Gardini, G Ercolani, A Riccobon, M Ravaioli, L Ridolfi, E Flamini, ... Journal of surgical oncology 87 (1), 46-52, 2004 | 62 | 2004 |
| Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients R Ridolfi, M Petrini, L Fiammenghi, M Stefanelli, L Ridolfi, M Ballardini, ... Journal of Translational Medicine 4, 1-11, 2006 | 55 | 2006 |
| Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial L Ridolfi, O Bertetto, A Santo, E Naglieri, M Lopez, F Recchia, P Lissoni, ... International journal of oncology 39 (4), 1011-1017, 2011 | 47 | 2011 |
| Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome L Ridolfi, M Petrini, L Fiammenghi, AM Granato, V Ancarani, E Pancisi, ... Melanoma research 21 (6), 524-529, 2011 | 43 | 2011 |
| Intralesional granulocyte‐monocyte colony‐stimulating factor followed by subcutaneous interleukin‐2 in metastatic melanoma: a pilot study in elderly patients L Ridolfi, R Ridolfi, A Ascari‐Raccagni, M Fabbri, S Casadei, A Gatti, ... Journal of the European Academy of Dermatology and Venereology 15 (3), 218-223, 2001 | 41 | 2001 |
| Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma L Ridolfi, R Ridolfi, A Riccobon, F De Paola, M Petrini, M Stefanelli, ... Journal of Immunotherapy 26 (2), 156-162, 2003 | 39 | 2003 |
| Anti-PD1 antibodies in patients aged≥ 75 years with metastatic melanoma: a retrospective multicentre study L Ridolfi, F De Rosa, E Petracci, ET Tanda, E Marra, J Pigozzo, ... Journal of geriatric oncology 11 (3), 515-522, 2020 | 38 | 2020 |
| Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in … F de Rosa, L Ridolfi, R Ridolfi, G Gentili, L Valmorri, O Nanni, M Petrini, ... Journal of Translational Medicine 12, 1-12, 2014 | 34 | 2014 |
| Dendritic cell vaccination in metastatic melanoma turns “non-T cell inflamed” into “T-cell inflamed” tumors J Bulgarelli, M Tazzari, AM Granato, L Ridolfi, S Maiocchi, F De Rosa, ... Frontiers in immunology 10, 2353, 2019 | 32 | 2019 |
| Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after … R Ridolfi, E Flamini, A Riccobon, F De Paola, R Maltoni, A Gardini, ... Cancer Immunology, Immunotherapy 46, 185-193, 1998 | 31 | 1998 |
| Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study M Guida, S Strippoli, M Maule, P Quaglino, A Ramondetta, VC Sileni, ... ESMO open 6 (2), 100064, 2021 | 30 | 2021 |
